Topical Ivermectin Rosacea — SCE Dermatology MCQ

Correct answer: D — Ivermectin has both anti-parasitic activity (killing Demodex folliculorum mites implicated in rosacea) and anti-inflammatory properties (inhibiting inflammatory cytokines)

The correct answer is D: ivermectin has both anti-parasitic activity (killing Demodex folliculorum mites implicated in rosacea) and anti-inflammatory properties (inhibiting inflammatory cytokines). Topical ivermectin 10 mg/g cream (Soolantra) is a NICE-evaluated treatment for papulopustular rosacea whose benefit derives from a dual mechanism rather than a single pathway. It exerts an acaricidal effect against Demodex folliculorum, a mite present in higher density on rosacea-affected skin and implicated in triggering innate immune activation and inflammation, while separately suppressing lipopolysaccharide-induced release of pro-inflammatory cytokines such as IL-1beta and TNF-alpha. This combined targeting of the presumed microbial trigger and the downstream inflammatory cascade distinguishes it from single-mechanism topical agents and explains its efficacy and durability in papulopustular rosacea. Why the other options are wrong: B. Antibiotic only: Ivermectin is an avermectin (anti-parasitic and anti-inflammatory agent), not an antibiotic, and has no direct antibacterial action; this option ignores its acaricidal and cytokine-inhibiting properties entirely. A. Anti-inflammatory only: This omits the acaricidal effect on Demodex folliculorum, which is a key part of ivermectin's proposed mechanism and a feature distinguishing it from agents like topical metronidazole. E. Vasoconstrictor: Ivermectin does not act on cutaneous vasculature; vasoconstriction is relevant to agents like brimonidine used for erythema, not to ivermectin's mechanism in papulopustular rosacea. C. Keratolytic: Ivermectin does not exfoliate or dissolve keratin; keratolysis is not part of its pharmacology and is irrelevant to rosacea's inflammatory and parasitic pathophysiology. Key point: Ivermectin cream is unique among topical rosacea treatments for combining direct killing of Demodex folliculorum with suppression of inflammatory cytokines, addressing both proposed drivers of papulopustular rosacea.

Reference: NICE, Evidence summary ESNM68: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream, full evidence summary, https://www.nice.org.uk/advice/esnm68/chapter/full-evidence-summary